L'annuaire du livre blanc de A à Z.

Catégorie : Commerce et économie: Filières spécialisées: Santé

"Asia is rapidly becoming a new frontier for drug development as Western companies seek to develop and register their products in Asia, while emerging Asian companies seek new capabilities to globalize products. As Asia continues to grow, the need for improved healthcare will drive the need for new medicines. To fully capitalize on the R&D opportunities presenting themselves in the growing markets of Asia, the biopharmaceutical industry will need to relinquish its faltering “go-at-it-alone” linear model of drug discovery and development in which one firm controls all the pieces, and shift towards a “wheel-and-spoke” model of multiple strategic partnerships with other biopharma and service providers companies with complementary strengths and capabilities."

Lire la suiteVisiter le siteSignaler une erreur

Catégorie : Commerce et économie: Filières spécialisées: Santé

"Apporter des réponses efficaces et innovantes aux pathologies auxquels sont exposées les populations, telle est la mission
quotidienne des Industriels de la santé. La santé est la première des préoccupations des citoyens du monde. Tous les acteurs de santé, dont évidemment les industriels, portent cette responsabilité vis-à-vis de la société."

Lire la suiteVisiter le siteSignaler une erreur

Catégorie : Commerce et économie: Filières spécialisées: Santé

"Spending on medicines will reach nearly $1,100Bn in 2015, reflecting a slowing growth rate of 3-6% over the five year period compared to 6.2% annual growth over the past five years. Absolute global spending growth is expected to be $210-240Bn, compared to $251Bn since 2005. The U.S. share of global spending will decline from 41% in 2005 to 31% in 2015, while the share of spending from the top 5 European countries will decline from 20% to 13% over the same period. Meanwhile, 17 high growth emerging markets led by China, will contribute 28% of total spending by 2015, up from only 12% in 2005. The next five years will also see an accelerating shift in spending toward generics, rising to 39% of spending in 2015, up from 20% in 2005."

Lire la suiteVisiter le siteSignaler une erreur